Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00413504 · ClinicalTrials.gov registry record · NA

Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism

A NA study, sponsored by Brigham and Women's Hospital.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT00413504: Completed NA study, sponsored by Brigham and Women's Hospital.

NCT00413504 is a NA study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 30 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00413504, a NA study, has completed, sponsored by Brigham and Women's Hospital.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

To determine whether fondaparinux as monotherapy without warfarin is effective and safe for long-term (90 days) treatment of DVT and/or PE, thus gaining new long-term experience and data using fondaparinux.

Interventions

  • DRUG Fondaparinux

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2006-04
Est. Completion 2007-07
Phase NA
Brigham and Women's Hospital

937 total trials

What the finished NCT00413504 record still lists

NCT00413504 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).

The record links to 0 conditions, and to 1 intervention - of which Fondaparinux is the first listed.

NCT00413504 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00413504 about?

NCT00413504 is a clinical study titled "Fondaparinux as Monotherapy for DVT and/or Pulmonary Embolism". To determine whether fondaparinux as monotherapy without warfarin is effective and safe for long-term (90 days) treatment of DVT and/or PE, thus gaining new long-term experience and data using fondaparinux.

What is the current status of trial NCT00413504?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2006-04. Estimated completion is 2007-07.

What interventions are being tested in trial NCT00413504?

The interventions under investigation include: Fondaparinux (DRUG).

Who is sponsoring clinical trial NCT00413504?

This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00413504's enrollment target sits among peer trials

30 1593rd of 2000 higher than 299 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00413504, the US trial registry maintained by the National Library of Medicine. NCT00413504 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.